Shattuck Labs, Inc. Depreciation and Amortization
Shattuck Labs, Inc. (STTK) reported Depreciation and Amortization of $3.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-03-05
- Shattuck Labs, Inc. depreciation, depletion and amortization for fiscal 2025 was $3.70M, a 2.63% decline from fiscal 2024.
- Shattuck Labs, Inc. depreciation, depletion and amortization for fiscal 2024 was $3.80M, a 5.00% decline from fiscal 2023.
- Shattuck Labs, Inc. depreciation, depletion and amortization for fiscal 2023 was $4.00M, a 29.03% increase from fiscal 2022.
- Shattuck Labs, Inc. depreciation, depletion and amortization for fiscal 2022 was $3.10M, a 121.43% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 12 month |
|---|---|
| 2025-12-31 | $3.70M 10-K · filed 2026-03-05 |
| 2024-12-31 | $3.80M 10-K · filed 2026-03-05 |
| 2023-12-31 | $4.00M 10-K · filed 2025-03-27 |
| 2022-12-31 | $3.10M 10-K · filed 2024-02-29 |
| 2021-12-31 | $1.40M 10-K · filed 2023-02-23 |
| 2020-12-31 | $600.00K 10-K · filed 2022-03-15 |
| 2019-12-31 | $500.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |